SCHEMBL6012368

SCHEMBL6012368

CC1(COc2cccc(N3CCN(C(=O)O)[C@H](Cc4ccc(OC(F)(F)F)cc4)C3)c2)Cn2cc([N+](=O)[O-])nc2O1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.61
PTGS1 P23219 1/20 0.58
SLC6A2 P23975 1/20 0.58
SLC6A4 P31645 1/20 0.58
CHRM1 P11229 2/20 0.41
NR1H2 P55055 4/20 0.36
NR1H3 Q13133 4/20 0.36
NOTUM Q6P988 1/20 0.36
CHRM2 P08172 1/20 0.36
ABHD6 Q9BV23 1/20 0.35
DAGLA Q9Y4D2 1/20 0.35
CACNA1C Q13936 1/20 0.34
SCN5A Q14524 1/20 0.34
CHRM4 P08173 2/20 0.34
FFAR4 Q5NUL3 1/20 0.33
ENPP2 Q13822 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6012362 1.00 KCNH2 (0.61) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010781 0.86 KCNH2 (0.65) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010784 0.86 KCNH2 (0.65) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010703 0.85 PTGS1 (0.54) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010713 0.85 PTGS1 (0.54) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010831 0.85 KCNH2 (0.53) KCNH2PTGS1SLC6A2SLC6A4NR1H2
SCHEMBL6010973 0.85 KCNH2 (0.59) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010822 0.85 KCNH2 (0.53) KCNH2PTGS1SLC6A2SLC6A4NR1H2
SCHEMBL6010969 0.85 KCNH2 (0.59) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6012358 0.84 KCNH2 (0.65) KCNH2PTGS1SLC6A2SLC6A4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KCNH2 3503/4885PTGS1 3838/4885SLC6A2 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.